Cardiac Marker Testing Market Report 2026

Cardiac Marker Testing Market Overview

• Cardiac Marker Testing market size has reached to $7.19 billion in 2025 • Expected to grow to $11.61 billion in 2030 at a compound annual growth rate (CAGR) of 10% • Growth Driver: Rising Cardiovascular Disease Incidence Fuels Growth In Cardiac Marker Testing Market • Market Trend: Advancements In Cardiac Marker Testing • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cardiac Marker Testing Market?

Cardiac marker testing refers to a series of diagnostic tests used to measure specific substances in the blood that can indicate damage or stress to the heart. These markers are often proteins or enzymes released into the bloodstream when the heart muscle is injured. Cardiac marker tests are crucial for diagnosing and evaluating conditions such as myocardial infarction (heart attack), heart failure, and other cardiac diseases. The main cardiac marker testing products are reagents, kits, and instruments. Reagents and kits are essential components used in cardiac marker testing that contain the necessary chemicals and materials required to perform diagnostic tests. It provides various types of biomarkers, including troponin I and T, creatine kinase-MB (CK-MB), natriuretic peptide, myoglobin, high-sensitivity C-reactive protein, and others, and it is applied in laboratory testing facilities, point-of-care testing facilities, and academic institutions.

What Is The Cardiac Marker Testing Market Growth Forecast?

The cardiac marker testing market size is expected to see rapid growth in the next few years. It will grow to $11.61 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to development of automated and portable cardiac marker testing devices, rising adoption of point-of-care diagnostics, integration with digital health platforms, growing geriatric population and cardiovascular risk, advancements in reagent and kit sensitivity. Major trends in the forecast period include rising adoption of high-sensitivity cardiac biomarker tests, expansion of point-of-care testing facilities, integration of automated analyzers and immunoassay systems, growing use of cardiac marker testing in preventive cardiology, increasing demand for portable diagnostic devices.

Global Cardiac Marker Testing Market Segmentation

1) By Product: Reagents And Kits, Instruments 2) By Biomarker Type: Troponin I And T, Creatine Kinase-MB (CK-MB), Natriuretic Peptide, Myoglobin, High-Sensitivity C-Reactive Protein, Other Biomarker Types 3) By Application: Laboratory Testing Facilities, Point-Of-Care Testing Facilities, Academic Institutions Subsegments: 1) By Reagents and Kits: Troponin Test Kits, B-type Natriuretic Peptide (BNP) Test Kits, Creatine Kinase-MB (CK-MB) Test Kits, Myoglobin Test Kits, Other Cardiac Biomarker Reagents 2) By Instruments: Point-Of-Care Testing Devices, Automated Analyzers, Immunoassay Systems, Portable Diagnostic Devices

What Is The Driver Of The Cardiac Marker Testing Market?

The rising incidence of cardiovascular diseases is expected to propel the growth of the cardiac marker testing market going forward. Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart failure, and stroke. The rising cases of cardiovascular diseases are caused due to an unhealthy diet, physical inactivity, tobacco use, harmful use of alcohol, and air pollution. Cardiac marker testing is required for cardiovascular diseases to accurately diagnose, assess the severity, and monitor the progression or response to treatment of heart conditions by detecting specific biomarkers released during myocardial injury. For instance, in January 2024, according to the American Heart Association, a US-based nonprofit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000, up 4.0% from 224.4 per 100,000 when compared to 2023. Therefore, the rising incidence of cardiovascular diseases drives the cardiac marker testing industry.

Key Players In The Global Cardiac Marker Testing Market

Major companies operating in the cardiac marker testing market are F. Hoffmann‑La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Tosoh Corporation, Guangzhou Wondfo Biotech Co. Ltd., Randox Laboratories Ltd., Getein Biotech Inc., Fujirebio Inc., Mayo Clinic Laboratories, Alere Inc., Nano‑Ditech Corporation, Ortho Clinical Diagnostics, QuidelOrtho Corporation, DiaSorin S.p.A., PerkinElmer Inc., Meso Scale Diagnostics LLC, Boditech Med Inc., Response Biomedical Corp.

Global Cardiac Marker Testing Market Trends and Insights

Major companies operating in the cardiac marker testing market are focused on developing technologically advanced products, such as cardiac assays, to provide valuable, precise information about heart health and function. Cardiac assays are diagnostic tests designed to measure biomarkers or other indicators in the blood or other samples to assess heart function, diagnose cardiovascular diseases, or evaluate the risk of heart-related conditions. For instance, in October 2023, Mindray, a China-based medical device company, launched the troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The hs-cTnI assay distinguishes itself with exceptional sensitivity, precision, and reliability, surpassing minimum requirements by achieving a 93% detection rate between the limit of detection (LoD) and the 99th percentile upper reference limit (URL) and maintaining an imprecision coefficient of variation (CV) below 5% at the 99th URL, making it highly effective in detecting myocardial injury. Mindray's NT-proBNP assay is an important cardiac marker for heart failure, showing high precision with a coefficient of variation (CV) of ≤5%. It also effectively minimizes interference from 55 common heart disease medications, ensuring accurate detection and management of heart failure.

What Are Latest Mergers And Acquisitions In The Cardiac Marker Testing Market?

In August 2024, VION Biosciences, a US-based life sciences platform acquired Ansh Labs for an undisclosed amount. Through this acquisition, VION Biosciences aims to strengthen its presence in the diagnostic sector, integrate advanced technologies, and expand its product offerings in immunoassay development. Ansh Labs is a US-based biotechnology company.

Regional Outlook

North America was the largest region in the cardiac marker testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Cardiac Marker Testing Market?

The cardiac marker testing market consists of revenues earned by entities by providing services such as homocysteine testing, cardiac stress testing, genetic testing for cardiovascular risk, remote monitoring and telemedicine services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiac marker testing market also includes sales of lipoprotein(a) test kits, cardiac biomarker panels, point-of-care testing devices and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.